-$0.14 EPS Expected for OraSure Technologies, Inc. (NASDAQ:OSUR) This Quarter

Wall Street analysts forecast that OraSure Technologies, Inc. (NASDAQ:OSURGet Rating) will post earnings per share (EPS) of ($0.14) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for OraSure Technologies’ earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.20). OraSure Technologies posted earnings of ($0.02) per share during the same quarter last year, which would indicate a negative year over year growth rate of 600%. The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that OraSure Technologies will report full-year earnings of ($0.42) per share for the current fiscal year, with EPS estimates ranging from ($0.66) to ($0.23). For the next year, analysts expect that the business will post earnings of ($0.24) per share, with EPS estimates ranging from ($0.41) to $0.17. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover OraSure Technologies.

OraSure Technologies (NASDAQ:OSURGet Rating) last posted its quarterly earnings data on Tuesday, May 10th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.14). The company had revenue of $67.71 million during the quarter, compared to the consensus estimate of $60.17 million. OraSure Technologies had a negative return on equity of 12.15% and a negative net margin of 19.25%. The firm’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same quarter last year, the company posted $0.05 earnings per share.

A number of research firms have recently weighed in on OSUR. StockNews.com lowered OraSure Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, May 11th. TheStreet lowered OraSure Technologies from a “c-” rating to a “d+” rating in a research note on Friday, March 4th. Citigroup dropped their price objective on OraSure Technologies from $12.00 to $10.00 in a research note on Wednesday, May 11th. Finally, Zacks Investment Research lowered OraSure Technologies from a “hold” rating to a “sell” rating in a research note on Thursday, May 12th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, OraSure Technologies has a consensus rating of “Hold” and a consensus target price of $12.17.

Shares of OSUR stock traded down $0.13 during trading on Thursday, hitting $2.90. The company had a trading volume of 265,640 shares, compared to its average volume of 1,379,298. The stock has a market capitalization of $210.13 million, a price-to-earnings ratio of -4.48 and a beta of -0.24. The stock’s 50-day moving average is $5.68 and its two-hundred day moving average is $7.42. OraSure Technologies has a 52 week low of $2.93 and a 52 week high of $13.57.

Institutional investors have recently made changes to their positions in the stock. 1832 Asset Management L.P. bought a new position in OraSure Technologies in the first quarter worth $40,000. Lazard Asset Management LLC raised its holdings in OraSure Technologies by 72.8% in the fourth quarter. Lazard Asset Management LLC now owns 7,737 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 3,260 shares in the last quarter. Legacy Advisors LLC bought a new position in OraSure Technologies in the first quarter worth $83,000. CIBC Asset Management Inc bought a new position in OraSure Technologies in the fourth quarter worth $92,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in OraSure Technologies by 61.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,871 shares of the medical instruments supplier’s stock worth $103,000 after purchasing an additional 4,522 shares in the last quarter. Institutional investors own 97.00% of the company’s stock.

OraSure Technologies Company Profile (Get Rating)

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

Featured Stories

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.